- ISIN
- SG9999014716
- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Nov 11, 2015
Highlights
- Market Cap
- $1.24B
- Enterprise Value
- $714.49M
- EPS (TTM)
- -$1.03
- Total Revenue (TTM)
- $71.80M
- Gross Profit (TTM)
- $29.09M
- EBITDA (TTM)
- -$184.40M
- Year Range
- $5.02 - $21.73
- Target Price
- $29.38
- ROA (TTM)
- -824.30%
- ROE (TTM)
- -35.88%
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
WVE Performance Chart
Wave Life Sciences Ltd. (WVE) is down 63.7% since the beginning of the year. At $6 per share, WVE is trading 71.6% below its 52-week high of $22. Investors who bought $1,000 worth of WVE shares 5 years ago would now be looking at an investment worth $877.
Loading charts...
Returns By Period
Wave Life Sciences Ltd. (WVE) has returned -63.71% so far this year and -6.09% over the past 12 months. Over the last ten years, WVE has returned -11.21% per year, falling short of the S&P 500 Index benchmark, which averaged 13.88% annually.
Wave Life Sciences Ltd.
- 1D
- 0.16%
- 1M
- -3.29%
- YTD
- -63.71%
- 6M
- -65.66%
- 1Y
- -6.09%
- 3Y*
- 18.16%
- 5Y*
- -2.60%
- 10Y*
- -11.21%
Benchmark (S&P 500 Index)
- 1D
- -0.37%
- 1M
- -0.01%
- YTD
- 9.16%
- 6M
- 8.64%
- 1Y
- 25.22%
- 3Y*
- 19.78%
- 5Y*
- 11.99%
- 10Y*
- 13.88%
WVE Monthly Returns History
Based on dividend-adjusted daily data since Nov 11, 2015, WVE's average daily return is +0.14%, while the average monthly return is +2.45%. At this rate, an investment would double in approximately 2.4 years.
Historically, 44% of months were positive and 56% were negative. The best month was Jun 2022 with a return of +132.1%, while the worst month was Dec 2019 at -75.8%. The longest winning streak lasted 3 consecutive months, and the longest losing streak was 6 months.
On a daily basis, WVE closed higher 49% of trading days. The best single day was Dec 8, 2025 with a return of +147.3%, while the worst single day was Dec 16, 2019 at -55.4%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -23.88% | 7.65% | -47.95% | -2.62% | -6.80% | -6.23% | -63.71% | ||||||
| 2025 | -6.47% | -8.64% | -23.56% | -4.46% | -22.15% | 8.15% | 24.62% | 18.52% | -23.75% | 23.50% | -14.16% | 119.07% | 37.43% |
| 2024 | -14.46% | 11.34% | 28.27% | -20.10% | 25.35% | -19.26% | 32.46% | -13.16% | 42.86% | 67.20% | 10.14% | -18.08% | 144.95% |
| 2023 | -29.57% | -14.81% | 3.10% | -7.85% | -0.75% | -8.08% | 20.05% | -0.46% | 32.18% | -6.43% | -1.30% | -4.90% | -27.86% |
| 2022 | -30.25% | 12.10% | -18.53% | -2.50% | -28.21% | 132.14% | -21.85% | 16.93% | 21.55% | 32.69% | -11.48% | 65.09% | 122.93% |
| 2021 | 29.22% | -7.47% | -40.38% | 9.63% | 11.22% | -2.63% | -17.27% | 14.88% | -22.59% | -6.33% | -15.03% | -19.49% | -60.10% |
Benchmark Metrics
Wave Life Sciences Ltd. has an annualized alpha of 20.93%, beta of 1.15, and R2 of 0.04 versus S&P 500 Index. Calculated based on daily prices since November 11, 2015.
- This stock tended to rise when S&P 500 Index fell (downside capture of -63.26%), but participation in market rallies was also limited (-43.75%) - a profile typical of counter-cyclical assets.
- R2 of 0.04 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 20.93%
- Beta
- 1.15
- R²
- 0.04
- Upside Capture
- -43.75%
- Downside Capture
- -63.26%
Return for Risk
Risk / Return Rank
WVE ranks 50 for risk / return — on par with similar stocks. You're getting a typical balance of risk and reward. Not a standout, but not a red flag either — a reasonable choice if other factors align with your goals.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for Wave Life Sciences Ltd. (WVE) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| WVE | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -2.07 | ||
| Sortino ratioReturn per unit of downside risk | -1.42 | ||
| Omega ratioGain probability vs. loss probability | 1.21 | 1.37 | -0.16 |
| Calmar ratioReturn relative to maximum drawdown | -0.08 | 2.78 | -2.87 |
| Martin ratioReturn relative to average drawdown | -0.15 | 12.44 | -12.59 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Wave Life Sciences Ltd.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Wave Life Sciences Ltd. was 97.77%, occurring on May 13, 2022. The portfolio has not yet recovered.
The current Wave Life Sciences Ltd. drawdown is 88.82%.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
Bear market2022 | -97.77%May 2022 | 3y 7mo | — | 7y 9moSep 2018 - now |
2017 bear market2017 | -61.44%Jul 2017 | 7mo 22d | 6mo 9d | 1y 1moNov 2016 - Jan 2018 |
2016 bear market2016 | -50.97%Feb 2016 | 1mo 25d | 29d | 2mo 24dDec 2015 - Mar 2016 |
2018 bear market2018 | -38.12%Jun 2018 | 4mo 5d | 3mo 1d | 7mo 6dFeb 2018 - Sep 2018 |
2016 bear market2016 | -36.57%Apr 2016 | 19d | 2mo 16d | 3mo 5dMar 2016 - Jun 2016 |
Drawdown Indicators
| WVE | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -97.77% | -56.78% | -40.99% |
Max Drawdown (1Y)Largest decline over 1 year | -73.44% | -9.10% | -64.34% |
Max Drawdown (3Y)Largest decline over 3 years | -73.44% | -18.90% | -54.54% |
Max Drawdown (5Y)Largest decline over 5 years | -82.89% | -25.43% | -57.46% |
Max Drawdown (10Y)Largest decline over 10 years | -97.77% | -33.92% | -63.85% |
Current DrawdownCurrent decline from peak | -88.82% | -1.80% | -87.02% |
Average DrawdownAverage peak-to-trough decline | -64.87% | -10.71% | -54.16% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 40.69% | 2.03% | +38.66% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Wave Life Sciences Ltd. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Wave Life Sciences Ltd. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for WVE relative to other companies in the Biotechnology industry. Currently, WVE has a P/S ratio of 15.3. This P/S ratio falls within the average range for the industry, suggesting the stock is fairly valued based on its revenue.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for WVE in comparison with other companies in the Biotechnology industry. Currently, WVE has a P/B value of 2.4. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with WVE
Add Wave Life Sciences Ltd. to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with WVE